Related Experiment Video
Updated: Sep 1, 2025
08:09
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
Published on: March 14, 2025
1.1K
Efficient derivation of chimeric-antigen receptor-modified TSCM cells
Emiko Kranz1, Charles J Kuhlmann2, Joshua Chan3
1Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, CA, United States.
Frontiers in Immunology
|August 15, 2022
Summary
A new protocol efficiently generates stem cell memory T (TSCM) cells for CAR T-cell therapy. This method enhances TSCM cell proportion, potentially improving CAR T-cell persistence and therapeutic efficacy.
Area of Science:
- Immunology
- Cell Biology
- Biotechnology
Background:
- Current CAR T-cell manufacturing yields limited long-lived memory T cells, specifically the stem cell memory T (TSCM) subset.
- TSCM cells possess self-renewal and differentiation capabilities crucial for sustained therapeutic effects.
- A standardized protocol for generating CAR TSCM cells is lacking, hindering therapeutic advancements.
Purpose of the Study:
- To develop a simplified and efficient protocol for deriving gene-modified TSCM cells.
- To investigate the potential of enhanced TSCM cell populations for improved CAR T-cell therapy.
Main Methods:
- Stimulation of naive CD8+ T cells with soluble anti-CD3 antibody.
- Culture of T cells with Interleukin-7 (IL-7) and Interleukin-15 (IL-15).
- Engineering TSCM cells with chimeric antigen receptors (CARs) targeting HIV-1 envelope protein and CD19.
Main Results:
- The simplified protocol successfully derived CD8+ T cells with TSCM phenotypes and oligopotent capabilities.
- In vitro expanded TSCM cells engineered with CARs demonstrated effector activity.
- CAR TSCM cells showed efficacy in a xenograft mouse model.
Conclusions:
- A simplified protocol enables efficient generation of CAR TSCM cells.
- This method may enhance CAR T-cell persistence and improve adoptive immunotherapy outcomes.
- Further research into this protocol could advance CAR T-cell therapy development.
